Immunology & Inflammation drugs

94 results

  • actemra

    (tocilizumab)
    Genentech, Inc.
    ACTEMRA (tocilizumab) is indicated for treating moderately to severely active rheumatoid arthritis, giant cell arteritis, systemic sclerosis-associated interstitial lung disease, polyarticular and systemic juvenile idiopathic arthritis, severe cytokine release syndrome from CAR T-cell therapy, and COVID-19 in hospitalized adults requiring respiratory support.

  • acthar

    (Repository Corticotropin)
    Mallinckrodt ARD LLC
    Acthar Gel is indicated for treating infantile spasms in infants under 2, acute exacerbations of multiple sclerosis in adults, and as adjunctive therapy for various rheumatic disorders. It is also used for certain collagen diseases, severe dermatologic and allergic conditions, ophthalmic inflammatory diseases, symptomatic sarcoidosis, and nephrotic syndrome.

  • actimmune

    (Interferon gamma-1b)
    Horizon Therapeutics USA, Inc.
    ACTIMMUNE is indicated for reducing serious infections in patients with Chronic Granulomatous Disease (CGD) and for delaying disease progression in severe, malignant osteopetrosis (SMO).

  • alrex

    (loteprednol etabonate)
    Bausch & Lomb Incorporated
    ALREX ophthalmic suspension is indicated for the temporary relief of signs and symptoms associated with seasonal allergic conjunctivitis.

  • anoro ellipta

    (umeclidinium bromide and vilanterol trifenatate)
    GlaxoSmithKline LLC
    ANORO ELLIPTA is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or asthma treatment, and its safety and effectiveness in asthma have not been established.

  • arcalyst

    (rilonacept)
    Kiniksa Pharmaceuticals (UK), Ltd.
    ARCALYST (rilonacept) is indicated for treating Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, as well as for maintaining remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) and treating recurrent pericarditis in patients aged 12 and older.

  • asceniv

    (HUMAN IMMUNOGLOBULIN G)
    ADMA Biologics, Inc.
    ASCENIV is indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12-17 years), including conditions such as congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

  • auvi-q

    (epinephrine)
    kaleo, Inc
    AUVI-Q® is indicated for the emergency treatment of Type I allergic reactions, including anaphylaxis due to insect stings, food, medications, and other allergens. It is intended for immediate self-administration in individuals at risk for anaphylaxis and is not a substitute for medical care.

  • bepreve

    (bepotastine besilate)
    Bausch & Lomb Incorporated
    BEPREVE® (bepotastine besilate ophthalmic solution) 1.5% is indicated for treating itching linked to allergic conjunctivitis symptoms.

  • berinert

    (HUMAN C1-ESTERASE INHIBITOR)
    CSL Behring GmbH
    BERINERT is indicated for the treatment of acute abdominal, facial, or laryngeal hereditary angioedema (HAE) attacks in both adult and pediatric patients. Its safety and efficacy for prophylactic therapy have not been established.